E-resources
Peer reviewed
Open access
-
Lim, D. Scott; Smith, Robert L.; Gillam, Linda D.; Zahr, Firas; Chadderdon, Scott; Makkar, Raj; von Bardeleben, Ralph Stephan; Kipperman, Robert M.; Rassi, Andrew N.; Szerlip, Molly; Goldman, Scott; Inglessis-Azuaje, Ignacio; Yadav, Pradeep; Lurz, Philipp; Davidson, Charles J.; Mumtaz, Mubashir; Gada, Hemal; Kar, Saibal; Kodali, Susheel K.; Laham, Roger; Hiesinger, William; Fam, Neil P.; Keßler, Mirjam; O’Neill, William W.; Whisenant, Brian; Kliger, Chad; Kapadia, Samir; Rudolph, Volker; Choo, Joseph; Hermiller, James; Morse, Michael A.; Schofer, Niklas; Gafoor, Sameer; Latib, Azeem; Koulogiannis, Konstantinos; Marcoff, Leo; Hausleiter, Jörg
JACC. Cardiovascular interventions, 12/2022, Volume: 15, Issue: 24Journal Article
Severe symptomatic degenerative mitral regurgitation (DMR) has a poor prognosis in the absence of treatment, and new transcatheter options are emerging. The CLASP IID (Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial) randomized trial (NCT03706833) is the first to evaluate the safety and effectiveness of the PASCAL system compared with the MitraClip system in patients with significant symptomatic DMR. This report presents the primary safety and effectiveness endpoints for the trial. Patients with 3+ or 4+ DMR at prohibitive surgical risk were assessed by a central screening committee and randomized 2:1 (PASCAL:MitraClip). Study oversight also included an echocardiography core laboratory and a clinical events committee. The primary safety endpoint was the composite major adverse event rate at 30 days. The primary effectiveness endpoint was the proportion of patients with mitral regurgitation (MR) ≤2+ at 6 months. A prespecified interim analysis in 180 patients demonstrated noninferiority of the PASCAL system vs the MitraClip system for the primary safety and effectiveness endpoints of major adverse event rate (3.4% vs 4.8%) and MR ≤2+ (96.5% vs 96.8%), respectively. Functional and quality-of-life outcomes significantly improved in both groups (P < 0.05). The proportion of patients with MR ≤1+ was durable in the PASCAL group from discharge to 6 months (PASCAL, 87.2% and 83.7% P = 0.317 vs discharge; MitraClip, 88.5% and 71.2% P = 0.003 vs discharge). The CLASP IID trial demonstrated safety and effectiveness of the PASCAL system and met noninferiority endpoints, expanding transcatheter treatment options for prohibitive surgical risk patients with significant symptomatic DMR. Display omitted
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.